Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis

Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic c...

Full description

Bibliographic Details

Published in:	Journal of Contemporary Medicine
Main Authors:	Ahmet Dirican, Gonca Akdere Ateş, Atike Pinar Erdoğan, Ferhat Ekinci, Özge Kama Başcı
Format:	Article
Language:	English
Published:	Rabia Yılmaz 2022-11-01
Subjects:	enzalutamid prostat kanseri böbrek yetmezliği enzalutamide prostate cancer renal failure
Online Access:	https://dergipark.org.tr/tr/download/article-file/2653132